TCR2 Therapeutics Inc.
TCRR · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $59 | $39 | $70 | $112 |
| - Cash | $14 | $33 | $54 | $44 |
| + Debt | $6 | $54 | $58 | $64 |
| Enterprise Value | $50 | $60 | $74 | $131 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$33 | -$2 | -$30 | -$30 |
| % Margin | – | – | – | – |
| Net Income | -$40 | -$61 | -$31 | -$32 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.03 | -1.56 | -0.79 | -0.82 |
| % Growth | 34% | -97.5% | 3.7% | – |
| Operating Cash Flow | -$40 | -$25 | -$26 | -$20 |
| Capital Expenditures | -$0 | -$2 | -$5 | -$6 |
| Free Cash Flow | -$40 | -$27 | -$31 | -$26 |